科研之友
微信
新浪微博
Facebook
分享链接
摘要
Introduction. Topiramate and onabotulinumtoxin A have proven to be effective in chronic migraine with or without medication abuse according to recent criteria of the International Headache Society%26apos;s Headache Classification. %26lt;br%26gt;Aims. To show that flunarizine is as effective as topiramate in cases of chronic migraine without medication abuse. %26lt;br%26gt;Patients and methods. We conducted a prospective, non-randomised, comparative study of two groups of patients paired by age and sex, with chronic migraine without abuse, who had been treated preventively for the first time with topiramate or flunarizine. %26lt;br%26gt;Results. Forty patients treated with flunarizine were assigned a patient of their same sex and age who was being treated with topiramate. The mean rate of reduction in intense migraines in the topiramate group was 59% and in the flunarizine group, 58.5% (p = 0.9444); the responder rate at four months of treatment did not show any significant differences either, the figures being 75% for topiramate and 70% for flunarizine (p = 0.6236). The mean reduction of other headaches in the topiramate group was 57% and in the flunarizine group, 64% (p = 0.4261); the responder rate at four months of treatment was similar in the two groups: 76%. The percentage of dropouts from treatment was higher with topiramate (19.5%) than with flunarizine (10%) (p = 0.3493). No serious side effects occurred in either of the groups. In all, 78.9% of the patients who took topiramate said they were satisfied with the drug versus 75% of those in the flunarizine group (p = 0.7903). %26lt;br%26gt;Conclusions. Flunarizine proved to be as effective as topiramate in the treatment of chronic migraine without medication abuse.
- 出版日期2013-10-16
